Uniphar AIM:UPR
- Founded
- 1994 · Dublin, Ireland
- Incorporated
- Ireland
- Chief executive
- Ger Rabbette
- Employees
- 3,589
- Reports in
- EUR
Irish healthcare services group operating across three divisions: supply chain and retail support for Irish pharmacies, medtech sales and distribution across Europe, and product access services helping pharma companies commercialise and distribute specialist medicines globally. Dual-listed on Euronext Dublin and AIM.
Read straight from the annual reports
342c at close on 2 Oct 2026 · 8 reported years, 2018–2025
| Line | FY201812/18 | FY201912/19 | FY202012/20 | FY202112/21 | FY202212/22 | FY202312/23 | FY202412/24 | FY202512/25 | FY2026unreported |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Gross profit | |||||||||
| Operating profit | |||||||||
| Adjusted operating profit | |||||||||
| Exceptional items | vs 5.3 | vs 14.4 | |||||||
| Net finance cost | |||||||||
| Profit before tax | |||||||||
| Adjusted profit before tax | |||||||||
| Tax charge | |||||||||
| Profit for the year | |||||||||
| EBITDA | |||||||||
| Adjusted minus statutory PBT | |||||||||
| Basic EPS | |||||||||
| Diluted EPS | |||||||||
| Adjusted EPS | |||||||||
| Dividend per share | — |
EUR millions, negatives in brackets. Per-share lines in cents, share counts in millions. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
8 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Global Sourcing demand for hard-to-source/unavailable medicines
Global Sourcing continues to perform strongly, with sustained demand for medicines that are difficult-to-source or unavailable through traditional channels
page 8Pharma Services commercialisation/outsourcing and Expanded Access Programmes
Pharma Services performed well in 2025 providing high-value advisory and commercialisation support across the full product lifecycle; EAP pipeline remains a key growth point
page 8Mix shift toward higher-volume, lower-margin Supply Chain & Retail revenue
Gross margin 14.9% in 2025 vs 15.4% in 2024, as SC&R (lowest-margin division) grew fastest in revenue terms
page 60Organic Gross Profit growth across all three divisions
Organic Gross Profit growth of 8.9%, the highest since IPO, driven by Medtech (+10.5%), Pharma (+15.5%) and SC&R (+4.2%)
page 13Group remains on track to reach its medium-term strategic goal of delivering €200m EBITDA by 2028, with at least 80% of that growth being organic.
page 7There were no material events subsequent to 31 December 2025 that would require adjustment to or disclosure in the financial statements.
page 92Progressive dividend policy. Proposed final dividend of €3.4m (€0.0131/ordinary share), subject to AGM approval, payable 15 May 2026; 2025 interim dividend of €1.8m (€0.0071/share) already paid; total 2025 shareholder dividend €5.2m (€0.0202/share), a 5% increase per share on 2024. A €35m share buyback (13,440,956 shares cancelled at weighted average €2.604) was completed in March 2025.
page 7PwC (Dublin) issued an unqualified/unmodified audit opinion; sole key audit matter was the goodwill impairment assessment (carrying value c.€500m, ~29% of total assets; management concluded no impairment required, auditors concurred). Overall group materiality €3.6m (c.5% of PBT before exceptional items). Directors concluded it is appropriate to adopt the going concern basis for at least 12 months from approval (23 February 2026), supported by significant headroom under the €400m RCF plus €150m accordion and €150m term loan facilities.
page 56- Economic, geopolitical and external environment risk — macroeconomic, regulatory, political and legal uncertainty across Ireland, UK, Europe, US and Asia-Pacific marketsp.31
- Acquisitions and Strategic Growth — failure to identify, execute or integrate acquisitions, or to manage organic growth/new market entry riskp.31
- Transformational project execution — delays, cost overruns or integration issues on multi-year strategic capex/transformation programmesp.32
- Talent Recruitment and Retention — failure to attract, develop, engage and retain a skilled workforce across geographiesp.31
Read from C001361-AR-2025-website.
10 annual reports read, FY2019 to FY2025
Open a year to see what its report said. Every line in it carries the page it was read from.
Sources: Company website (10)
FY2026Next report expected 5 Mar 2027